FMF FIRST TRIMESTER SCREEN Test
Test Cost: AED 510.0
Test Name: FMF FIRST TRIMESTER SCREEN Test
Components: Price: 510.0 AED
Sample Condition: 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Provide maternal Date of Birth (dd/mm/yy), LMP, USG report between 11-13 weeks gestation including CRL, NT & Nasal Bone, number of fetuses; Diabetic status, body weight; IVF, Smoking & Previous h/o Trisomy 21. Duly filled Patient demographic details in Maternal Serum Screen Requisition Form (Form 11) is mandatory. Valid between 9-13 weeks gestation (Ideal 10-13 weeks).
Report Delivery: Sample Tue / Thu / Sat by 9 am; Report Same day
Method: ECLIA
Test type: Prenatal Diagnosis
Doctor: Gynecologist
Test Department: IMMUNOASSAY
Pre Test Information: Duly filled Patient demographic details in Maternal Serum Screen Requisition Form (Form 11) is mandatory. Valid between 9-13 weeks gestation (Ideal 10-13 weeks).
Test Details
The FMF (Fetal Medicine Foundation) First Trimester Screen is a prenatal screening test that combines an ultrasound examination and blood tests to assess the risk of certain chromosomal abnormalities in the fetus. It is typically performed between 11 to 14 weeks of pregnancy.
The test involves two components:
- Ultrasound Examination: This involves measuring the nuchal translucency (NT), which is the fluid-filled space at the back of the baby’s neck. Increased NT thickness is associated with an increased risk of certain chromosomal abnormalities, such as Down syndrome. The ultrasound also evaluates other fetal structures and confirms the gestational age.
- Blood Tests: Two blood tests are performed as part of the First Trimester Screen. The first is a maternal blood test that measures the levels of pregnancy-associated plasma protein-A (PAPP-A), and the second is a blood test that measures the levels of human chorionic gonadotropin (hCG). Deviations from normal levels of these hormones can indicate an increased risk of chromosomal abnormalities.
The results of the ultrasound and blood tests are combined with the mother’s age and gestational age to calculate the overall risk of chromosomal abnormalities. This risk is presented as a ratio, such as 1 in 500, indicating the likelihood of the fetus having a chromosomal abnormality.
It is important to note that the FMF First Trimester Screen is a screening test, not a diagnostic test. If the screening results indicate a high risk, further diagnostic tests, such as chorionic villus sampling (CVS) or amniocentesis, may be recommended to confirm the presence of a chromosomal abnormality.
It is advisable to discuss the benefits, limitations, and potential risks of the FMF First Trimester Screen with a healthcare provider to make an informed decision about whether to undergo the test.
Test Name | FMF FIRST TRIMESTER SCREEN Test |
---|---|
Components | |
Price | 510.0 AED |
Sample Condition | 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Provide maternal Date of Birth (dd\/mm\/yy), LMP, USG report between 11-13 weeks gestation including CRL, NT & Nasal Bone, number of fetuses; Diabetic status, body weight; IVF, Smoking & Previous h\/o Trisomy 21. Duly filled Patient demographic details in Maternal Serum Screen Requisition Form (Form 11) is mandatory. Valid between 9-13 weeks gestation (Ideal 10-13 weeks). |
Report Delivery | SampleTue / Thu / Sat by 9 am; Report Same day |
Method | ECLIA |
Test type | Prenatal Diagnosis |
Doctor | Gynecologist |
Test Department: | IMMUNOASSAY |
Pre Test Information | Duly filled Patient demographic details in Maternal Serum Screen Requisition Form (Form 11) is mandatory. Valid between 9-13 weeks gestation (Ideal 10-13 weeks). |
Test Details | The FMF (Fetal Medicine Foundation) First Trimester Screen is a prenatal screening test that combines an ultrasound examination and blood tests to assess the risk of certain chromosomal abnormalities in the fetus. It is typically performed between 11 to 14 weeks of pregnancy. The test involves two components: 1. Ultrasound Examination: This involves measuring the nuchal translucency (NT), which is the fluid-filled space at the back of the baby’s neck. Increased NT thickness is associated with an increased risk of certain chromosomal abnormalities, such as Down syndrome. The ultrasound also evaluates other fetal structures and confirms the gestational age. 2. Blood Tests: Two blood tests are performed as part of the First Trimester Screen. The first is a maternal blood test that measures the levels of pregnancy-associated plasma protein-A (PAPP-A), and the second is a blood test that measures the levels of human chorionic gonadotropin (hCG). Deviations from normal levels of these hormones can indicate an increased risk of chromosomal abnormalities. The results of the ultrasound and blood tests are combined with the mother’s age and gestational age to calculate the overall risk of chromosomal abnormalities. This risk is presented as a ratio, such as 1 in 500, indicating the likelihood of the fetus having a chromosomal abnormality. It is important to note that the FMF First Trimester Screen is a screening test, not a diagnostic test. If the screening results indicate a high risk, further diagnostic tests, such as chorionic villus sampling (CVS) or amniocentesis, may be recommended to confirm the presence of a chromosomal abnormality. It is advisable to discuss the benefits, limitations, and potential risks of the FMF First Trimester Screen with a healthcare provider to make an informed decision about whether to undergo the test. |